Bangladesh Country Commercial Guide
Learn about the market conditions, opportunities, regulations, and business conditions in bangladesh, prepared by at U.S. Embassies worldwide by Commerce Department, State Department and other U.S. agencies’ professionals
Select Country Guide
Healthcare and Pharmaceuticals
Last published date:

Overview

The healthcare sector in Bangladesh has experienced increased growth in recent years.  Bangladesh is the only least developed country (LDC) that meets nearly 98 percent of its domestic demand for pharmaceutical products, with a market size of approximately $3 billion.  In addition, Bangladeshi pharmaceutical products are exported to approximately 150 countries and generated $169 million in fiscal year 2020-21.  With an annual two-digit growth rate, the Bangladesh pharmaceutical industry is now heading towards self–sufficiency in meeting local demand.  There are more than 300 small, medium, and large enterprises operating in the country producing pharmaceuticals; the top ten producers make up approximately two-thirds of the market.

The Government of Bangladesh encourages foreign companies to partner with local companies in producing drugs and high-tech and specialized products.  Regulations have eased, allowing foreign companies to export medical products to Bangladesh.

Bangladesh offers opportunities for U.S. exporters of high-end medical equipment, surgical instruments, diagnostic equipment, and services.  Imported medicines and medical devices are subject to customs duties depending on types and classes.  Anti-cancer drugs, vaccines, hormonal contraceptives, and other products can be imported without tax.  The medical device sector is not currently strictly regulated, although a policy for doing so has been drafted and awaits approval.  To enter the healthcare sector in Bangladesh a company is required to provide the necessary application and supporting documents.  For pharmaceutical companies, applications go to the Directorate General of Drug Administration (DGDA).

The Ministry of Health and Family Welfare (MOHFW) is responsible for formulating national-level policy, planning, and decision-making concerning healthcare and education.  The national-level policies, plans, and decisions are translated into action by various implementing authorities and healthcare delivery systems across the country, from the national to the community level.  The Ministry and its relevant regulatory bodies also have indirect control over the healthcare system of the NGOs and the private sector.  The majority of high-quality medical institutions are centered in the city of Dhaka which acts as the hub for disseminating medical services across the country.

Any direct foreign investor in Bangladesh must submit a project proposal to the Bangladesh Investment Authority (BIDA) for review before receiving approval.  Once registered with BIDA, companies investing in hospitals and medical education must obtain a license from the Directorate General for Health Services (DGHS).  Pharmaceutical and medical device companies in turn must go through DGDA for licensing.  However, companies seeking these licenses need to be vetted by the Ministry of Health and Family Welfare, the main entity responsible for all healthcare sub-sectors.

Leading Sub-Sectors

Medical Devices; Clinical Lab Trials; Waste Management; Safe Water Drinking; Sanitation Coverage.

Opportunities

Dietary Supplements; Pharmacovigilance; Cosmetics; Veterinary and Human Vaccines; Disease Modifying Drugs; Hormonal Therapies.

Resources

Bangladesh Investment Development Authority (BIDA)

Bangladesh Association of Pharmaceutical Industries

 

×

Global Business Navigator Chatbot Beta

Welcome to the Global Business Navigator, an artificial intelligence (AI) Chatbot from the International Trade Administration (ITA). This tool, currently in beta version testing, is designed to provide general information on the exporting process and the resources available to assist new and experienced U.S. exporters. The Chatbot, developed using Microsoft’s Azure AI services, is trained on ITA’s export-related content and aims to quickly get users the information they need. The Chatbot is intended to make the benefits of exporting more accessible by understanding non-expert language, idiomatic expressions, and foreign languages.

Limitations

As a beta product, the Chatbot is currently being tested and its responses may occasionally produce inaccurate or incomplete information. The Chatbot is trained to decline out of scope or inappropriate requests. The Chatbot’s knowledge is limited to the public information on the Export Solutions web pages of Trade.gov, which covers a wide range of topics on exporting. While it cannot provide responses specific to a company’s product or a specific foreign market, its reference pages will guide you to other relevant government resources and market research. Always double-check the Chatbot’s responses using the provided references or by visiting the Export Solutions web pages on Trade.gov. Do not use its responses as legal or professional advice. Inaccurate advice from the Chatbot would not be a defense to violating any export rules or regulations.

Privacy

The Chatbot does not collect information about users and does not use the contents of users’ chat history to learn new information. All feedback is anonymous. Please do not enter personally identifiable information (PII), sensitive, or proprietary information into the Chatbot. Your conversations will not be connected to other interactions or accounts with ITA. Conversations with the Chatbot may be reviewed to help ITA improve the tool and address harmful, illegal, or otherwise inappropriate questions.

Translation

The Chatbot supports a wide range of languages. Because the Chatbot is trained in English and responses are translated, you should verify the translation. For example, the Chatbot may have difficulty with acronyms, abbreviations, and nuances in a language other than English.

Privacy Program | Information Quality Guidelines | Accessibility